Academia’s contribution to drug discovery: current status and perspectives in Japan

Author:

OKUYAMA Ryo1

Affiliation:

1. College of International Management, Ritsumeikan Asia Pacific University, Jumonjibaru, Beppu, Oita 874-8577, Japan

Publisher

AMED iD3 Catalyst Unit

Subject

General Medicine

Reference27 articles.

1. 1. Japanese Science and Technology Indicators 2022 https://www.nistep.go.jp/research/science-and-technology-indicators-and-scientometrics/indicators accessed on 2023/4/30.

2. 2. Trade Statistics of Japan Ministry of Finance for fiscal year 2022 https://www.customs.go.jp/toukei/shinbun/trade-st/2022/202228g.xml accessed on 2023/4/30.

3. 3. Nakao, A. 2022. Nationality of companies creating the world’s top-selling drugs −trends in 2021− https://www.jpma.or.jp/opir/news/067/bi62u8000000045j-att/67_11.pdf accessed on 2023/4/30.

4. 4. Okuyama, R. 2020. Science-based Innovation. Chapter 1, Jichosha, Tokyo.

5. 5. Kneller, R. 2010. The importance of new companies for drug discovery: origins of a decade of new drugs. Nat. Rev. Drug Discov. 9: 867–882.

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3